Theravance Biopharma, Inc. Research and Development Expense
Theravance Biopharma, Inc. (TBPH) reported Research and Development Expense of $4.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Theravance Biopharma, Inc. research and development expense for the quarter ending 2026-06-30 was $4.71M, a 55.08% decline year-over-year.
- Theravance Biopharma, Inc. research and development expense for the quarter ending 2026-03-31 was $5.83M, a 49.10% decline year-over-year.
- Theravance Biopharma, Inc. research and development expense for the quarter ending 2025-12-31 was $7.36M, a 22.14% decline year-over-year.
- Theravance Biopharma, Inc. research and development expense for the quarter ending 2025-09-30 was $8.11M, a 12.47% decline year-over-year.
- Theravance Biopharma, Inc. research and development expense for fiscal 2025 was $37.41M, a 0.61% decline from fiscal 2024.
- Theravance Biopharma, Inc. research and development expense for fiscal 2024 was $37.64M, a 7.33% decline from fiscal 2023.
- Theravance Biopharma, Inc. research and development expense for fiscal 2023 was $40.62M, a 35.92% decline from fiscal 2022.
- Theravance Biopharma, Inc. research and development expense for fiscal 2022 was $63.39M, a 67.27% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.71M 10-Q · filed 2026-08-11 | $10.54M 10-Q · filed 2026-08-11 | $17.90M derived: sum of 3 quarters · filed 2026-08-11 | $26.01M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $5.83M 10-Q · filed 2026-05-07 | $13.19M derived: sum of 2 quarters · filed 2026-05-07 | $21.30M derived: sum of 3 quarters · filed 2026-05-07 | $31.79M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $15.47M derived: sum of 2 quarters · filed 2026-03-23 | $25.96M derived: sum of 3 quarters · filed 2026-08-11 | $37.41M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $8.11M 10-Q · filed 2025-11-12 | $18.60M derived: sum of 2 quarters · filed 2026-08-11 | $30.05M 10-Q · filed 2025-11-12 | $39.51M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $10.49M 10-Q · filed 2026-08-11 | $21.94M 10-Q · filed 2026-08-11 | $31.39M derived: sum of 3 quarters · filed 2026-08-11 | $40.66M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $11.45M 10-Q · filed 2026-05-07 | $20.91M derived: sum of 2 quarters · filed 2026-05-07 | $30.17M derived: sum of 3 quarters · filed 2026-05-07 | $40.13M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $18.72M derived: sum of 2 quarters · filed 2026-03-23 | $28.68M derived: sum of 3 quarters · filed 2026-03-23 | $37.64M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $9.27M 10-Q · filed 2025-11-12 | $19.22M derived: sum of 2 quarters · filed 2025-11-12 | $28.19M 10-Q · filed 2025-11-12 | $36.50M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $9.95M 10-Q · filed 2025-08-13 | $18.92M 10-Q · filed 2025-08-13 | $27.23M derived: sum of 3 quarters · filed 2025-08-13 | $35.55M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $8.97M 10-Q · filed 2025-05-12 | $17.28M derived: sum of 2 quarters · filed 2025-05-12 | $25.59M derived: sum of 3 quarters · filed 2025-05-12 | $35.02M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $16.62M derived: sum of 2 quarters · filed 2025-03-07 | $26.05M derived: sum of 3 quarters · filed 2025-03-07 | $40.62M 10-K · filed 2025-03-07 | |||
| 2023-09-30 | $8.31M 10-Q · filed 2024-11-14 | $17.74M derived: sum of 2 quarters · filed 2024-11-14 | $32.31M 10-Q · filed 2024-11-14 | $47.66M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $9.43M 10-Q · filed 2024-08-08 | $24.00M 10-Q · filed 2024-08-08 | $39.34M derived: sum of 3 quarters · filed 2024-08-08 | $49.21M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $14.57M 10-Q · filed 2024-05-15 | $29.92M derived: sum of 2 quarters · filed 2024-05-15 | $39.79M derived: sum of 3 quarters · filed 2024-05-15 | $54.71M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $15.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $25.21M derived: sum of 2 quarters · filed 2024-03-01 | $40.14M derived: sum of 3 quarters · filed 2024-03-01 | $63.39M 10-K · filed 2024-03-01 | |||
| 2022-09-30 | $9.87M 10-Q · filed 2023-11-09 | $24.79M derived: sum of 2 quarters · filed 2023-11-09 | $48.04M 10-Q · filed 2023-11-09 | $48.69M 10-Q · filed 2022-11-09 | $79.27M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $14.92M 10-Q · filed 2023-08-09 | $15.57M 10-Q · filed 2022-08-08 | $38.18M 10-Q · filed 2023-08-09 | $38.82M 10-Q · filed 2022-08-08 | $69.40M derived: sum of 3 quarters · filed 2023-08-09 | $113.14M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $23.25M 10-Q · filed 2023-05-10 | $54.48M derived: sum of 2 quarters · filed 2023-05-10 | $98.22M derived: sum of 3 quarters · filed 2023-05-10 | $149.31M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $31.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $74.97M derived: sum of 2 quarters · filed 2023-03-01 | $126.06M derived: sum of 3 quarters · filed 2023-03-01 | $193.66M 10-K · filed 2023-03-01 | |||
| 2021-09-30 | $43.74M 10-Q · filed 2022-11-09 | $94.83M derived: sum of 2 quarters · filed 2022-11-09 | $162.43M 10-Q · filed 2022-11-09 | $227.60M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $51.09M 10-Q · filed 2022-08-08 | $118.69M 10-Q · filed 2022-08-08 | $183.86M derived: sum of 3 quarters · filed 2023-03-01 | $251.23M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $67.60M 10-Q · filed 2022-05-06 | $132.76M derived: sum of 2 quarters · filed 2023-03-01 | $200.13M derived: sum of 3 quarters · filed 2023-03-01 | $262.54M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $65.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $132.54M derived: sum of 2 quarters · filed 2023-03-01 | $194.94M derived: sum of 3 quarters · filed 2023-03-01 | $260.95M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $67.37M 10-Q · filed 2021-11-08 | $129.78M derived: sum of 2 quarters · filed 2021-11-08 | $195.79M 10-Q · filed 2021-11-08 | $262.81M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $62.40M 10-Q · filed 2021-08-05 | $128.42M 10-Q · filed 2021-08-05 | $195.44M derived: sum of 3 quarters · filed 2022-02-28 | $247.45M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $66.01M 10-Q · filed 2021-05-06 | $133.04M derived: sum of 2 quarters · filed 2022-02-28 | $185.04M derived: sum of 3 quarters · filed 2022-02-28 | $231.44M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $67.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $119.03M derived: sum of 2 quarters · filed 2022-02-28 | $165.43M derived: sum of 3 quarters · filed 2022-02-28 | $219.25M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $52.01M 10-Q · filed 2020-11-09 | $98.41M derived: sum of 2 quarters · filed 2020-11-09 | $152.22M 10-Q · filed 2020-11-09 | $204.49M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | $46.40M 10-Q · filed 2020-08-10 | $100.22M 10-Q · filed 2020-08-10 | $152.49M derived: sum of 3 quarters · filed 2021-02-26 | $205.18M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | $53.82M 10-Q · filed 2020-05-08 | $106.09M derived: sum of 2 quarters · filed 2021-02-26 | $158.78M derived: sum of 3 quarters · filed 2021-02-26 | $207.40M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $52.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $104.96M derived: sum of 2 quarters · filed 2021-02-26 | $153.58M derived: sum of 3 quarters · filed 2021-02-26 | $201.35M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $52.69M 10-Q · filed 2019-11-08 | $101.31M derived: sum of 2 quarters · filed 2019-11-08 | $149.08M 10-Q · filed 2019-11-08 | $200.13M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $48.62M 10-Q · filed 2019-08-05 | $96.39M 10-Q · filed 2019-08-05 | $147.44M derived: sum of 3 quarters · filed 2020-02-27 | $186.78M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | $47.77M 10-Q · filed 2019-05-10 | $98.82M derived: sum of 2 quarters · filed 2020-02-27 | $138.16M derived: sum of 3 quarters · filed 2020-02-27 | $181.09M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $51.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $90.39M derived: sum of 2 quarters · filed 2020-02-27 | $133.32M derived: sum of 3 quarters · filed 2020-02-27 | $173.89M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $39.34M 10-Q · filed 2018-11-08 | $82.27M derived: sum of 2 quarters · filed 2018-11-08 | $122.83M 10-Q · filed 2018-11-08 | $164.85M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-06-30 | $42.93M 10-Q · filed 2018-08-02 | $83.49M 10-Q · filed 2018-08-02 | $125.51M derived: sum of 3 quarters · filed 2019-02-28 | $157.46M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-03-31 | $40.56M 10-Q · filed 2018-05-09 | $82.58M derived: sum of 2 quarters · filed 2019-02-28 | $114.53M derived: sum of 3 quarters · filed 2019-02-28 | $146.60M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | $42.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $73.97M derived: sum of 2 quarters · filed 2019-02-28 | $106.03M derived: sum of 3 quarters · filed 2019-02-28 | $141.71M 10-K · filed 2019-02-28 | |||
| 2016-09-30 | $31.95M 10-Q · filed 2017-11-08 | $64.02M derived: sum of 2 quarters · filed 2017-11-08 | $99.70M 10-Q · filed 2017-11-08 | $132.10M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-06-30 | $32.07M 10-Q · filed 2017-08-09 | $67.75M 10-Q · filed 2017-08-09 | $100.15M derived: sum of 3 quarters · filed 2018-02-28 | $130.52M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-03-31 | $35.68M 10-Q · filed 2017-05-10 | $68.08M derived: sum of 2 quarters · filed 2018-02-28 | $98.45M derived: sum of 3 quarters · filed 2018-02-28 | $128.82M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2015-12-31 | $32.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $62.77M derived: sum of 2 quarters · filed 2018-02-28 | $93.15M derived: sum of 3 quarters · filed 2018-02-28 | $129.16M 10-K · filed 2018-02-28 | |||
| 2015-09-30 | $30.37M 10-Q · filed 2016-11-09 | $60.74M derived: sum of 2 quarters · filed 2016-11-09 | $96.76M 10-Q · filed 2016-11-09 | $138.96M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $30.38M 10-Q · filed 2016-08-09 | $66.40M 10-Q · filed 2016-08-09 | $108.59M derived: sum of 3 quarters · filed 2017-03-01 | $146.91M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $36.02M 10-Q · filed 2016-05-10 | $78.21M derived: sum of 2 quarters · filed 2017-03-01 | $116.53M derived: sum of 3 quarters · filed 2017-03-01 | $162.82M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $42.19M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $80.52M derived: sum of 2 quarters · filed 2017-03-01 | $126.80M derived: sum of 3 quarters · filed 2017-03-01 | $168.52M 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $38.32M 10-Q · filed 2015-11-12 | $84.61M derived: sum of 2 quarters · filed 2015-11-12 | $126.33M 10-Q · filed 2015-11-12 | $158.80M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2014-06-30 | $46.28M 10-Q · filed 2015-08-13 | $88.01M 10-Q · filed 2015-08-13 | $120.48M derived: sum of 3 quarters · filed 2016-03-11 | $152.78M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2014-03-31 | $41.72M 10-Q · filed 2015-05-13 | $74.19M derived: sum of 2 quarters · filed 2016-03-11 | $106.49M derived: sum of 3 quarters · filed 2016-03-11 | $136.89M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2013-12-31 | $32.47M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $64.77M derived: sum of 2 quarters · filed 2016-03-11 | $95.17M derived: sum of 3 quarters · filed 2016-03-11 | $120.58M 10-K · filed 2016-03-11 | |||
| 2013-09-30 | $32.30M 10-Q · filed 2014-11-12 | $62.70M derived: sum of 2 quarters · filed 2014-11-12 | $88.11M 10-Q · filed 2014-11-12 | ||||
| 2013-06-30 | $30.40M 10-Q · filed 2014-08-14 | $55.81M 10-Q · filed 2014-08-14 | |||||
| 2013-03-31 | $25.41M 10-Q · filed 2014-06-24 | ||||||
| 2012-12-31 | $114.00M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |